Latest: FDA Approves New Biosimilar for Oncology Treatment

#VisualAbstract: Perioperative Durvalumab increased Survival in Gastric and Gastroesopha-geal Junction Cancer

0 Mins

Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc.Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

The post #VisualAbstract: Perioperative Durvalumab increased Survival in Gastric and Gastroesopha-geal Junction Cancer first appeared on 2 Minute Medicine.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago